Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1

International Journal of Molecular Medicine

Volumn 30, Issue 6, 2012, Pages 1473-1480

  Bujor, Andreea M ^a   Haines, Paul ^a   Padilla, Cristina ^a   Christmann, Romy B ^a   Junie, Monica ^b   Sampaio Barros, Percival D ^c   Lafyatis, Robert ^a   Trojanowska, Maria ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Ciprofloxacin; Collagen; DNA methyltransferase 1; Fibrosis; Friend leukemia integration factor 1; Matrix metalloproteinase 1; Systemic sclerosis

Indexed keywords

CIPROFLOXACIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; DNA METHYLTRANSFERASE 1; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; SMAD1 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR FLI 1; TRANSFORMING GROWTH FACTOR BETA; UO 126;

ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTERSTITIAL LUNG DISEASE; LUNG FIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; TRANSCRIPTION INITIATION;

CASE-CONTROL STUDIES; CELLS, CULTURED; CIPROFLOXACIN; COLLAGEN TYPE I; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 1; PROTO-ONCOGENE PROTEIN C-FLI-1; SCLERODERMA, SYSTEMIC; SKIN; UP-REGULATION;

EID: 84869381400     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1150     Document Type: Article

References (39)

1. De Sarro A and De Sarro G: Adverse reactions to fluoroquinolones. an overview on mechanistic aspects. Curr Med Chem 8: 371-384, 2001. (Pubitemid 32409786)
2. Lin HC, Yang YY, Tsai TH, et al: The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. J Hepatol 54: 1145-1153, 2011.
3. Zhang M, Song G and Minuk GY: Effects of hepatic stimulator substance, herbal medicine, selenium/vitamin E, and ciprofloxacin on cirrhosis in the rat. Gastroenterology 110: 1150-1155, 1996.
4. Reviglio VE, Hakim MA, Song JK and O'Brien TP: Effect of topical fluoroquinolones on the expression of matrix metalloproteinases in the cornea. BMC Ophthalmol 3: 10, 2003.
5. Sharma C, Velpandian T, Baskar Singh S, Ranjan Biswas N, Bihari Vajpayee R and Ghose S: Effect of fluoroquinolones on the expression of matrix metalloproteinase in debrided cornea of rats. Toxicol Mech Methods 21: 6-12, 2011.
6. Buyten J, Kaufman G and Ryan M: Effects of ciprofloxacin/dexamethasone and ofloxacin on tympanic membrane perforation healing. Otol Neurotol 28: 887-890, 2007. (Pubitemid 47511561)
7. Tsai WC, Hsu CC, Chen CP, et al: Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen. J Orthop Res 29: 67-73, 2011.
8. Corps AN, Harrall RL, Curry VA, Fenwick SA, Hazleman BL and Riley GP: Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1beta in human tendon-derived cells. A potential mechanism of fluoroquinolone-induced tendinopathy. Arthritis Rheum 46: 3034-3040, 2002. (Pubitemid 35315898)
9. Corps AN, Harrall RL, Curry VA, Hazleman BL and Riley GP: Contrasting effects of fluoroquinolone antibiotics on the expression of the collagenases, matrix metalloproteinases (MMP)-1 and -13, in human tendon-derived cells. Rheumatology (Oxford) 44: 1514-1517, 2005. (Pubitemid 41742467)
10. Sendzik J, Shakibaei M, Schafer-Korting M, Lode H and Stahlmann R: Synergistic effects of dexamethasone and quinolones on human-derived tendon cells. Int J Antimicrob Agents 35: 366-374, 2010.
11. Goto K, Yabe K, Suzuki T, Takasuna K, Jindo T and Manabe S: Gene expression profiles in the articular cartilage of juvenile rats receiving the quinolone antibacterial agent ofloxacin. Toxicology 249: 204-213, 2008.
12. Ruben EC, Manuel VR, Agustin OR, Huerta M, Antonio FM and Ivan DE: Ciprofloxacin utility as antifibrotic in the skin of patients with scleroderma. J Dermatol 37: 323-329, 2010.
13. Truong AH and Ben-David Y: The role of Fli-1 in normal cell function and malignant transformation. Oncogene 19: 6482-6489, 2000. (Pubitemid 32108438)
14. Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK and Trojanowska M: Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 276: 20839-20848, 2001.
15. Kubo M, Czuwara-Ladykowska J, Moussa O, et al: Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 163: 571-581, 2003. (Pubitemid 36909419)
16. Asano Y, Markiewicz M, Kubo M, Szalai G, Watson DK and Trojanowska M: Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol 29: 425-434, 2009.
17. Nakerakanti SS, Kapanadze B, Yamasaki M, Markiewicz M and Trojanowska M: Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 281: 25259-25269, 2006. (Pubitemid 44401913)
18. Haines P, Samuel GH, Cohen H, Trojanowska M and Bujor AM: Caveolin-1 is a negative regulator of MMP-1 gene expression in human dermal fibroblasts via inhibition of Erk1/2/Ets1 signaling pathway. J Dermatol Sci 64: 210-216, 2011.
19. Bujor AM, Nakerakanti S, Morris E, Hant FN and Trojanowska M: Akt inhibition up-regulates MMP1 through a CCN2-dependent pathway in human dermal fibroblasts. Exp Dermatol 19: 347-354, 2010.
20. Bu S, Yamanaka M, Pei H, et al: Dihydrosphingosine 1-phosphate stimulates MMP1 gene expression via activation of ERK1/2-Ets1 pathway in human fibroblasts. FASEB J 20: 184-186, 2006. (Pubitemid 43100508)
21. Jinnin M, Ihn H, Mimura Y, Asano Y, Yamane K and Tamaki K: Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves Ets1 and Fli1. Nucleic Acids Res 33: 3540-3549, 2005. (Pubitemid 41430577)
22. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y and Tamaki K: Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol 175: 7708-7718, 2005. (Pubitemid 41713471)
23. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K and Tamaki K: Epidermal growth factor affects the synthesis and degradation of type I collagen in cultured human dermal fibroblasts. Matrix Biol 25: 202-212, 2006. (Pubitemid 43729072)
24. Jun JB, Kuechle M, Min J, et al: Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J Invest Dermatol 124: 298-303, 2005. (Pubitemid 40175874)
25. Bujor AM, Asano Y, Haines P, Lafyatis R and Trojanowska M: The c-Abl tyrosine kinase controls protein kinase Cdeltainduced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis Rheum 63: 1729-1737, 2011.
26. Pannu J, Asano Y, Nakerakanti S, et al: Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 58: 2528-2537, 2008.
27. Mori Y, Chen SJ and Varga J: Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 48: 1964-1978, 2003. (Pubitemid 36828692)
28. Bujor AM, Pannu J, Bu S, Smith EA, Muise-Helmericks RC and Trojanowska M: Akt blockade downregulates collagen and upregulates MMP1 in human dermal fibroblasts. J Invest Dermatol 128: 1906-1914, 2008. (Pubitemid 352001221)
29. Wang Y, Fan PS and Kahaleh B: Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 54: 2271-2279, 2006. (Pubitemid 44051084)
30. Williams RJ III, Attia E, Wickiewicz TL and Hannafin JA: The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med 28: 364-369, 2000. (Pubitemid 30394760)
31. Tsai WC, Hsu CC, Tang FT, Wong AM, Chen YC and Pang JH: Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells. Arthritis Rheum 58: 1657-1663, 2008. (Pubitemid 351847518)
32. Tsai WC, Hsu CC, Chen HC, et al: Ciprofloxacin-mediated inhibition of tenocyte migration and down-regulation of focal adhesion kinase phosphorylation. Eur J Pharmacol 607: 23-26, 2009.
33. Takeda K, Hatamochi A, Ueki H, Nakata M and Oishi Y: Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 103: 359-363, 1994. (Pubitemid 24329757)
34. Elkareh J, Periyasamy SM, Shidyak A, et al: Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy. Am J Physiol Renal Physiol 296: F1219-F1226, 2009.
35. Sakthianandeswaren A, Curtis JM, Elso C, et al: Fine mapping of Leishmania major susceptibility Locus lmr2 and evidence of a role for Fli1 in disease and wound healing. Infect Immun 78: 2734-2744, 2010.
36. Abraham D: Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? Rheumatology (Oxford) 47 (Suppl 5): v8-v9, 2008.
37. Farina G, Lemaire R, Pancari P, Bayle J, Widom RL and Lafyatis R: Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta. Ann Rheum Dis 68: 435-441, 2009.
38. Farina G, Lafyatis D, Lemaire R and Lafyatis R: A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 62: 580-588, 2010.
39. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM and Leask A: CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 276: 10594-10601, 2001. (Pubitemid 38089227)